Loading stock data…
Maze Therapeutics, Inc. (MAZE)
$29.00+0.57 (+2.00%)
Market ClosedLast close Jun 29
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Maze Therapeutics, Inc. in the Healthcare sector is trading at $29.00 with a market capitalization of $1.4B. Wall Street consensus targets $62.55 (11 analysts), implying a +115.7% move over the next 12 months. The stock is currently 46% below its 52-week high of $53.65, remaining 15.1% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 88 is overbought against a weak tape. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +115.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 88 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $20.00M | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$26.55M↑ | -$38.06M↓ | -$32.97M↑ | -$36.47M↓ | -$35.40M |
| Net Income | -$24.21M↑ | -$34.57M↓ | -$30.09M↑ | -$33.68M↓ | -$32.79M |
Peer Comparison
JNJUNHPFE
Fundamentals
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibit...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.38B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-35.86%
Volume
Today's trading volume
771,505
Recent News
What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?
This clinical-stage biotech targeting kidney and metabolic diseases reported a notable insider sale, recent filings show.
Maze Therapeutics Phase 2 Kidney Data Sparks Questions On Upside And Risk
Maze Therapeutics (NasdaqGM:MAZE) reported positive topline results from its Phase 2 HORIZON trial of MZE829 in APOL1-mediated kidney disease. The company plans to advance MZE829 into a pivotal trial and shared updates on its broader clinical pipeline. Maze Therapeutics focuses on genetically informed therapies, and MZE829 targets APOL1-mediated kidney disease, an area with limited treatment options today. For investors, this Phase 2 readout matters because it adds clinical detail around a...
Maze Therapeutics (MAZE): 8 Oversold Stocks to Buy Right Now
Maze Therapeutics Inc. (NASDAQ:MAZE) is one of the oversold stocks to buy right now. On May 12, Maze Therapeutics highlighted in their corporate and financial update positive topline data from the Phase 2 HORIZON trial of MZE829. The trial evaluated the oral inhibitor in patients with APOL1-mediated kidney disease/AMKD. The results provided clinical proof-of-concept, showing […]
Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors?
This clinical-stage biotech advancing precision medicines reported a notable insider sale amid strong one-year share performance.
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares
Maze Therapeutics is a U.S. biotech advancing clinical-stage precision medicines for renal and metabolic diseases.